BioCentury | May 6, 2019
Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

...milestones. Launched in 2011 by co-founder Ben Cravatt of Scripps Research and sole institutional investor Cardinal Partners...
BioCentury | Apr 30, 2019
Finance

How Nextech-led round will help Vividion to POC

...Investments participated in the B round as did existing investors Arch Venture Partners, Versant Ventures, Cardinal Partners...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Clarke will resign from the board, effective Jan. 10. Clarke is a managing partner at Cardinal Partners...
BioCentury | Feb 4, 2017
Finance

Proteome roam

...the human proteome and expediting their translation. Participation in last week’s round included existing investor Cardinal Partners...
BioCentury | Feb 3, 2017
Financial News

Vividion completes venture financing

...A round co-led by Arch Venture Partners and Versant Ventures on Feb. 2. Existing investor Cardinal Partners...
BioCentury | Feb 2, 2017
Financial News

Vividion launches with $50M series A round

...Arch Venture Partners and Versant Ventures co-led the round and were joined by existing investor Cardinal Partners...
BioCentury | Apr 1, 2015
Financial News

aTyr raises $76M in series E

...fund, also participated, but did not specify which ones. Its prior investors include Alta Partners, Cardinal Partners...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...rare diseases related to the immune system $105 Series B, C, D, debt Alta Partners, Cardinal Partners...
...Phase II $68 Series A, B, C Advanced Technology Ventures, Astellas Venture, Bessemer Venture Partners, Cardinal Partners...
BioCentury | Mar 10, 2014
Strategy

Abiding its time

...funding and disclosed upfront payments. Abide raised $6.6 million in a series A round from Cardinal Partners...
BioCentury | Mar 3, 2014
Company News

Abide Therapeutics, Celgene deal

...Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal Partners...
Items per page:
1 - 10 of 48
BioCentury | May 6, 2019
Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

...milestones. Launched in 2011 by co-founder Ben Cravatt of Scripps Research and sole institutional investor Cardinal Partners...
BioCentury | Apr 30, 2019
Finance

How Nextech-led round will help Vividion to POC

...Investments participated in the B round as did existing investors Arch Venture Partners, Versant Ventures, Cardinal Partners...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Clarke will resign from the board, effective Jan. 10. Clarke is a managing partner at Cardinal Partners...
BioCentury | Feb 4, 2017
Finance

Proteome roam

...the human proteome and expediting their translation. Participation in last week’s round included existing investor Cardinal Partners...
BioCentury | Feb 3, 2017
Financial News

Vividion completes venture financing

...A round co-led by Arch Venture Partners and Versant Ventures on Feb. 2. Existing investor Cardinal Partners...
BioCentury | Feb 2, 2017
Financial News

Vividion launches with $50M series A round

...Arch Venture Partners and Versant Ventures co-led the round and were joined by existing investor Cardinal Partners...
BioCentury | Apr 1, 2015
Financial News

aTyr raises $76M in series E

...fund, also participated, but did not specify which ones. Its prior investors include Alta Partners, Cardinal Partners...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...rare diseases related to the immune system $105 Series B, C, D, debt Alta Partners, Cardinal Partners...
...Phase II $68 Series A, B, C Advanced Technology Ventures, Astellas Venture, Bessemer Venture Partners, Cardinal Partners...
BioCentury | Mar 10, 2014
Strategy

Abiding its time

...funding and disclosed upfront payments. Abide raised $6.6 million in a series A round from Cardinal Partners...
BioCentury | Mar 3, 2014
Company News

Abide Therapeutics, Celgene deal

...Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal Partners...
Items per page:
1 - 10 of 48